Medical Diagnostics and Therapeutic Interventions

Nuclear medicine involves the use of radioactive isotopes, known as radiopharmaceuticals, for diagnostic and therapeutic purposes. For diagnostic imaging, radiopharmaceuticals are administered to patients, and the emitted radiation is detected by specialised cameras, such as gamma cameras or PET scanners. This allows for the visualisation of organ function and the detection of abnormalities. In therapeutic interventions, radiopharmaceuticals are used to deliver targeted radiation to diseased tissues, such as tumours. This can be achieved through systemic administration, where the radiopharmaceutical circulates throughout the body, or through localised delivery, where it is injected directly into the tumour. Nuclear medicine offers several advantages over other imaging and treatment modalities. It provides functional information about organs and tissues, allowing for the early detection of diseases. It also enables targeted therapy, minimising damage to healthy tissues. This field plays a crucial role in the diagnosis and treatment of various diseases, including cancer, cardiovascular diseases, and neurological disorders.

Diagnostic Imaging: Uses radiopharmaceuticals to visualise organ function.
Targeted Radionuclide Therapy: Uses radiopharmaceuticals to deliver radiation to diseased tissues.
Positron Emission Tomography (PET): Uses positron-emitting radiopharmaceuticals for imaging.
Single-Photon Emission Computed Tomography (SPECT): Uses gamma-emitting radiopharmaceuticals for imaging.

Cancer Diagnosis and Treatment: Use of PET and SPECT for tumour imaging and targeted radionuclide therapy.
Cardiovascular Imaging: Assessment of blood flow and heart function using SPECT.
Neurological Imaging:Diagnosis of neurological disorders using PET and SPECT.
Thyroid Disease Treatment: Use of radioactive iodine for thyroid cancer and hyperthyroidism.

Radiological risks involve the exposure of patients and medical personnel to ionising radiation. For source-based reactor production and handling of radiopharmaceuticals, challenges include managing the radioactive inventory and waste. For electricity-generated production in cyclotrons, hazards involve prompt radiation during the production cycle. In all clinical settings, personnel follow strict safety protocols, including shielding and monitoring, to ensure doses remain within safe limits.

Deployment is heavily influenced by the isotope supply chain. Source-based isotopes from reactors require complex, time-sensitive logistics and account for the costs of management of sources. Electricity-generated isotopes produced in on-site cyclotrons require high capital investment and a stable power supply. General challenges include the high cost of equipment and the need for specialised medical training.

There are no proliferation risks as there is no nuclear material involved in this application.